2024-06-11 16:22:10 ET
Vertex Pharmaceuticals Incorporated (VRTX)
Goldman Sachs 45th Annual Global Healthcare Conference
June 11, 2024, 11:20 AM ET
Company Participants
David Altshuler - Chief Scientific Officer
Charles Wagner - CFO
Conference Call Participants
Salveen Richter - Goldman Sachs
Presentation
Salveen Richter
Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have the Vertex team here with us. Today, we do have David Altshuler, Chief Scientific Officer; as well as Charlie Wagner, CFO.
Question-and-Answer Session
Q - Salveen Richter
Maybe to start here, could you give us a snapshot of the business today and what we should anticipate in terms of strategy and commercial execution and pipeline in the second half of the year?
Charles Wagner
Yes. Listen, Salveen, thank you for hosting. We're happy to be here and good morning, everybody. I would just say this is an incredibly exciting time at Vertex and the Company has never been in a stronger position. If you listen to our recent Q1 earnings call, we continue to grow in CF, TRIKAFTA continues to grow. We're expanding geographically. We are increasing our penetration into younger age groups and the business just continues to execute very consistently and well.
Not only are we growing in CF, we continue to innovate. There's a lot of interest, of course, in our collaboration with Moderna for our mRNA program for CF, and we'll have more to say on that program late this year, early next year. I would say significantly, 2024 also represents an important milestone in terms of commercial diversification for the Company with the launch of CASGEVY, our therapy for sickle cell disease and beta thalassemia....
Read the full article on Seeking Alpha
For further details see:
Vertex Pharmaceuticals Incorporated (VRTX) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)